Centre Hospitalier De Libourne Robert Boulin
- Address
- 112 Rue De La Marne, 33500 Libourne, France
Centre Hospitalier De Libourne Robert Boulin - Clinical Research Center
The Centre Hospitalier De Libourne Robert Boulin is an active clinical research center participating in diverse multi-center therapeutic trials across multiple medical specialties. The center demonstrates particular expertise in oncology, hematology, and immunological disorders, contributing to innovative treatment developments in both solid tumors and hematological malignancies.
- Head and neck cancers including squamous cell carcinomas with advanced radiotherapy and immunotherapy combination protocols
- Hematological malignancies, particularly multiple myeloma with post-transplant maintenance therapies and novel biologic agents
- Neurological conditions including multiple sclerosis with disease-modifying therapy optimization and treatment de-escalation strategies
- Respiratory diseases such as asthma and COPD with evaluation of new therapeutic agents and biologics
The research center participates in Phase II and III clinical trials evaluating cutting-edge treatments for autoimmune conditions including rheumatoid arthritis, granulomatosis with polyangiitis, and systemic sclerosis. Additionally, the center contributes to studies in lymphoproliferative disorders including B-cell lymphomas and follicular lymphoma, as well as specialized research in Behçet's disease uveitis and chronic inflammatory demyelinating polyneuropathy, demonstrating comprehensive expertise across complex medical conditions requiring sophisticated therapeutic approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 51 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Libourne Robert Boulin
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy and Safety of Tocilizumab Versus Adalimumab in Severe Uveitis Associated with Behçet’s Disease: A Multicenter Randomized Trial | Assistance Publique Hopitaux De Paris | Phase II | Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 51 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 5 | Unknown | 2019-01-24 | 2026-06-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.